Chemistry: molecular biology and microbiology – Vector – per se
Reexamination Certificate
2007-08-14
2007-08-14
Foley, Shanon (Department: 1642)
Chemistry: molecular biology and microbiology
Vector, per se
C435S810000, C424S199100
Reexamination Certificate
active
10746558
ABSTRACT:
Mutations to the tumor suppressor protein p53 have been observed in 40-60% of all human cancers. These mutations are often associated with high nuclear and cytoplasmic concentrations of p53. Since many tumors exhibit highly elevated p53 levels, the protein is an attractive target for cancer immunotherapy. Unfortunately, p53 is an autoantigen that is likely to be tolerated as a self-protein by the immune system. The present invention is based on the discovery that this self-tolerance can be overcome by administration of recombinant modified vaccinia Ankara (MVA) containing a nucleic acid that encodes p53 (rMVAp53). The invention discloses a method of generating a p53-specific CTL-response to tumor cells expressing mutated p53 by administering a composition comprising rMVAp53. Administration of rMVAp53 decreases tumor development, tumor growth, and mortality in a variety of malignant cell types. These effects are enhanced by administration of CTLA-4 blocker and/or CpG oligodeoxynucleotide immunomodulators.
REFERENCES:
patent: 5185146 (1993-02-01), Altenburger
patent: 6045802 (2000-04-01), Schlom et al.
patent: 6410010 (2002-06-01), Zhang
Glazko et al (Biochemica et Biophysica Acta, 2004, 1679:95-106).
Ober et al (J of Virology, 2002, 76:7713-7723).
Timiryasova et al (International Journal of Oncology, 1999, 14:845-854).
Carroll et al (Vaccine, 1997, 15:387-394, IDS).
Stratagene 1988 catalog (p. 39).
Timiryasova et al (International Journal of Oncology, 1999, 14:845-854).
Carroll et al (Vaccine, 1997, 15:387-394, IDS).
Stratagene 1988 catalog (p. 39).
Allred, D.C., et al., “Biomarkers in early breach neoplasia,”J. Cell Biochem Suppl1993; 17G:125-131.
Antoine, G., et al., “The complete genomic sequence of the modified vaccinia Ankara strain: comparison with other orthopoxviruses,”Virology1998; 244:365-396.
Baines, J. et al., “Immune-mediated tumor regression induced by CpG-containing oligodeoxynucleotides,”Clin Cancer Res2003; 9:2693-2700.
Ballas, Z.K., et al., “Divergent therapeutic and immunologic effects of oligodeoxynucleotides with distinct CpG motifs,”J Immunol2001; 167:4878-4886.
Baral, R.N., et al., “Immunostimulatory CpG oligonucleotides enhance the immune response of anti-idiotype vaccine that mimics carcinoembryonic antigen,”Cancer Immunol Immunother2003; 52:317-327.
Berns, E.M., et al., “p53 protein accumulation predicts poor response to tamoxifen therapy of patients with recurrent breast cancer,”J Clin Oncol1998; 16:121-127.
Berns, E.M., et al., “Complete sequencing of TP53 predicts poor response to systemic therapy of advanced breast cancer,”Cancer Res2000; 60:2155-2162.
Berson, J.F., et al., “A seven-transmembrane domain receptor involved in fusion and entry of T-cell-tropic human immunodeficiency virus type 1 strain,”J Virol1996; 70:6288-6295.
Blanchard, T.J., et al., “Modified vaccinia virus Ankara undergoes limited replication in human cells and lacks several immunomodulatory proteins: implications for use as a human vaccine,”J Gen Virol1998; 79(Pt 5):1159-1167.
Bruggerman, M., et al., “Human antibody production in transgenic mice: expression from 100 kb of the human IgH locus,”Eur J Immunol1991; 5:1323-1326.
Carpentier, A.F., et al., “Oligodeoxynucleotides containing CpG motifs can induce rejection of a neuroblastoma in mice,”Cancer Res1999; 59:5429-5432.
Carroll, M.W., et al., “Host range and cytopathogenicity of the highly attenuated MVA strain of vaccinia virus: propagation and generation of recombinant viruses in a nonhuman mammalian cell line,”Virology1997a; 238:198-211.
Carroll, M.W., et al., “Highly attenuated modified vaccinia virus Ankara (MVA) as an effective recombinant vector: a murine tumor model,”Vaccine1997b; 15:387-394.
Chakrabarti, S., et al., “Vaccinia virus expression vector: coexpression of beta-galactosidase provides visual screening of recombinant virus plaques,”Mol Cell Biol1985; 5:3403-3409.
Chu, R.S., et al., “CpG oligodeoxynucleotides act as adjuvants that switch on T helper 1 (Th1) immunity,”J Exp Med1997; 186:1623-1631.
Collier, L.H., “Safety of recombinant vaccinia vaccines,”Lancet1991; 337:1035-1036.
Davila, E., et al., “Repeated administration of cytosine-phosphorothiolated guanine-containing oligonucleotides together with peptide/protein immunization results enhanced CTL responses with anti-tumor activity,”J Immunol2000; 165:539-547.
DeLeo, A.B., et al., “Cell surface antigens of chemically induced sarcomas of the mouse. I. Murine leukemia virus-related antigens and alloantigens on cultured fibroblasts and sarcoma cells: description of a unique antigen on BALB/c Meth A sarcoma,”J Exp Med1977; 146:720-734.
Dialynas, D.P., et al., “Characterization of the murine antigenic determinant, designated L3T4a, recognized by monoclonal antibody GK1.5: expression of L3T3a by functional T cell clones appears to correlate primarily with class II MHC antigen-reactivity,”Immunol Rev1983; 74:29-56.
Diamond, D.J., et al., “Development of a candidate HLA A*0201 restricted peptide-based vaccine against human cytomegalovirus infection,”Blood1997; 90:1751-1767.
Drexler, I., et al., “Modified vaccinia virus Ankara for delivery of human tyrosinase as melanoma-associated antigen: induction of tyrosi,”Cancer Res1999; 59:4955-4963.
Egen, J.G., et al., “CTLA-4: new insights into its biological function and use in tumor immunotherapy,”Nat Immunol2002; 3:611-618.
Eliyahu, D., et al., “Wild-type p53 can inhibit oncogene-mediated focus formation,”Proc Natl Acad Sci USA1989; 86:8763-8767.
Elkhuizen, P.H., et al., “High local recurrence risk after breast-conserving therapy in node-negative premenopausal breast cancer patients is greatly reduced by one course of perioperative chemotherapy: A European Organization for Research and Treatment of Cancer Breast Cancer Cooperative Group Study,”J Clin Oncol2000; 18:1075-1083.
Erdile, L.F., et al., “CD40 activation enhances the magnitude of cellular immune responses against p53 but not the avidity of the effectors,”Cancer Immunol Immunother2000; 49:410-416.
Espenschied, J., et al., “CTLA-4 blockade enhances the therapeutic effect of an attenuated poxvirus vacinne targeting p53 in an established murine tumor model,”J Immunol2003; 170:3401-3407.
Finlay, C.A., et al., “Activating mutations for transformation by p53 produce a gene product that forms an hsc70-p53 complex with an altered half-life,”Mol Cell Biol1998; 8:531-539.
Finlay, C.A., et al., “The p53 proto-oncogene can act as a suppressor of transformation,”Cell1989; 57:1083-1093.
Foote, J., et al., Antibody framework residues affecting the conformation of the hypervariable loops,J. Mol Bol1992; 224(2):487-499.
Gibson, L., et al., “Human Cytomegalovirus Proteins pp65 and IE1 are Common Targets for CD8+ T cell Responses in Children with Congenital and Postnatal HCMV infection,”J Immunol, in press.
Gurney, E.G., et al., “Monoclonal antibodies against simian virus 40 T antigens: evidence for distinct subclasses of large T antigen and for similarities among nonviral T antigens,”J Virol1980; 34:752-763.
Hainaut, P., et al., “p53 and human cancer: the first ten thousand mutations,”Adv Cancer Res2000; 77:81-137.
Halevy, O., et al., “Frequent p53 mutations in chemically induced murine fibrosarcoma,”Oncogene1991; 6:1593-1600.
He, T.C., et al., “A simplified system for generating recombinant adenoviruses,”Proc Natl Acad Sci USA1998; 95:2509-2514.
Heckelsmiller, K., et al., “Combined dendritic cell- and CpG oligonucleotide-based immune therapy cures large tumors that resist chemotherapy,”Eur J Immunol2002; 32:3235-3245.
Hemmi, H., et al., “A Toll-like receptor recognizes bacterial DNA,”Nature2000; 40
Diamond Don J.
Ellenhorn Joshua D. I.
City of Hope
Foley Shanon
Goddard Laura B
Perkins Coie LLP
Wise Michael J.
LandOfFree
Modified vaccinia Ankara expressing p53 in cancer immunotherapy does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Modified vaccinia Ankara expressing p53 in cancer immunotherapy, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Modified vaccinia Ankara expressing p53 in cancer immunotherapy will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3845510